News
Straumann Group announces new Executive Management Board members to support growth strategy
Straumann Group announces new Executive Management Board members to support growth strategy
Straumann Group ernennt neue Geschäftsleitungsmitglieder, um Wachstumsstrategie weiter voranzutreiben
Straumann Group ernennt neue Geschäftsleitungsmitglieder, um Wachstumsstrategie weiter voranzutreiben
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Sonova concludes 2021-22 share buyback and will start a new three-year buyback program of up to CHF 1.5 billion
Sonova concludes 2021-22 share buyback and will start
a new three-year buyback program of up to CHF 1.5 billion
Sonova schliesst Aktienrückkauf 2021-22 ab und lanciert neues dreijähriges Rückkaufprogramm von bis zu CHF 1,5 Mrd.
Sonova schliesst Aktienrückkauf 2021-22 ab und lanciert neues
dreijähriges Rückkaufprogramm von bis zu CHF 1,5 Mrd.
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Kuros Biosciences reports results for the full year 2021
Kuros Biosciences reports results for the full year 2021
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Evolva grew product-related revenue by 40% in 2021
Evolva grew product-related revenue by 40% in 2021
Urteil in Patentverletzungsprozess - Advanced Bionics legt Berufung ein
Urteil in Patentverletzungsprozess -
Advanced Bionics legt Berufung ein
Judgment in patent infringement case - Advanced Bionics files appeal
Judgment in patent infringement case - Advanced Bionics files appeal
Geschäftsjahr 2021: Markante Umsatz- und Gewinnsteigerung
Geschäftsjahr 2021: Markante Umsatz- und Gewinnsteigerung
2021 financial year: Sharp rise in sales and profits
2021 financial year: Sharp rise in sales and profits
Sonova schliesst Übernahme der Sennheiser Consumer Division ab und schafft neues Geschäftsfeld
Sonova schliesst Übernahme der Sennheiser Consumer Division ab und schafft neues Geschäftsfeld
Sonova completes acquisition of the Sennheiser Consumer Division and forms a new business
Sonova completes acquisition of the Sennheiser Consumer Division and forms a new business
Sonova schliesst Übernahme von Alpaca Audiology ab
Sonova schliesst Übernahme von Alpaca Audiology ab